This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AstraZeneca, Handa, Par get US antitrust claims trimmed in Seroquel XR case

( July 5, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Plaintiffs’ claims accusing AstraZeneca of entering into an illegal reverse payment agreement with Accord Healthcare over the drug Seroquel XR are overly conclusory, a US federal judge ruled. District Judge Colm F. Connolly determined that there are no non-conclusory factual allegations that plausibly imply it would have been economically rational for AstraZeneca to enter into an alternative settlement agreement with Accord when Accord conceded that it infringed the patent and had no allegation that the patent was invalid or weak such that it could have prevailed or believed that it could have prevailed at trial on its invalidity defenses. Connolly maintained plaintiffs claims based on AstraZeneca’s deal with Handa Pharmaceuticals, concluding that but for its agreement with AstraZeneca, Handa could have released a generic competitor. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections